21 Jun 2018

Human Tissue Experts REPROCELL Launch New Customized Primary Cell Isolation Services

REPROCELL’s BioServe and Biopta tissue procurement networks combine to create a new service isolating human primary cells.

13 Jun 2018

REPROCELL's footprint extends to serve life sciences in India

REPROCELL India (formerly BioServe Biotechnologies) is a state-of-the-art biotechnology company with a mission to serve the life sciences research ecosystem.

25 May 2018

Do animal experiments translate to humans? A report by Elsevier and Bayer uses big data to shed new light on a hotly debated topic

At REPROCELL, we are continually striving to expand our range of human fresh tissue and 3D models of drug safety and efficacy. REPROCELL hosts the only catalogue of human fresh tissue assays with searchable categories of tissue type, receptor and endpoints across a range of therapeutic areas.

18 May 2018

Factors to consider when planning a iPSC reprogramming project

When you are considering beginning a project involving iPSC reprogramming, there are several factors to consider when choosing a reprogramming technology and a service provider.

1 2 3 4 >>

Biopta is attending the Safety Pharmacology Society conference in Prague


Biopta are attending the Safety Pharmacology Society conference in Prague, Monday 28th Sep - Thursday 1st October.

Come and meet Biopta at booth 3 to find out how predictive tests in fresh human tissues can add significant value to your compounds.

Dr Keith Bowers will be delivering a presentation titled 'The Relevance of Functional Studies with Fresh Human Isolated Tissues for the Assessment of Safety and Efficacy' on Wednesday 30th September Meeting Hall V at 17:15. An overview of the presentation is provided below.

Human functional tissues are increasingly being used to assess the safety of preclinical drug candidates. Human fresh tissues have long been considered the closest possible model of human pharmacology because they closely retain the tissue phenotype and can be used to measure a wide range of pharmacological responses. Despite this, relatively little drug development is conducted using fresh human tissue because of the perceived logistical and ethical difficulties surrounding the availability of tissue and practicalities of experimental work.

Overcoming the barriers to uptake of human tissue research remains a challenge and will be supported by clear evidence of the benefits of such an approach. It is also important to point out that such assays do not by themselves completely replace existing safety tests but contribute to a platform of evidence that increases the probability of clinical success and reduces the risk that species differences will go undetected.

Live chat by BoldChat